Eli Lilly Completes Acquisition of AtaiBeckley

INDIANAPOLIS – Eli Lilly & Co. has closed its acquisition of AtaiBeckley Inc., the New York-based biopharmaceutical company developing psychedelic-derived therapies for treatment-resistant mental health conditions. The transaction cleared its final U.S. regulatory checkpoint when the premerger antitrust review waiting period expired on August 28, completing the last material hurdle before formal close.

Under the terms announced on July 16, Lilly paid $6.75 per share in cash [an aggregate equity value of approx. $2.8 billion] with AtaiBeckley shareholders also eligible for contingent value rights of up to $2.50 per share tied to clinical and regulatory milestones, bringing total potential consideration to $3.8 billion. The per-share price represented a 40% premium to AtaiBeckley’s 30-day volume-weighted average trading price.

The asset driving the transaction is BPL-003, a proprietary intranasal formulation of mebufotenin benzoate, better known as 5-MeO-DMT. The compound holds FDA Breakthrough Therapy Designation and entered two simultaneous Phase 3 studies [ReConnection-1 and ReConnection-2] in Q2 2026, following a supportive End-of-Phase 2 meeting with the FDA in March. Phase 2b data across 193 patients showed statistically significant reductions in standardized depression scores lasting up to eight weeks on a single dose, with most participants discharge-ready roughly 100 minutes after administration.

Lilly’s chief scientific officer, Dan Skovronsky, noted that BPL-003 works by physically altering neuronal connections rather than adjusting neurotransmitter levels, and that the practical result could be a treatment delivered only a few times a year. Beyond BPL-003, AtaiBeckley’s pipeline includes VLS-01, a DMT buccal film targeting treatment-resistant depression, and EMP-01, an (R)-MDMA formulation in Phase 2 for social anxiety disorder.

AtaiBeckley itself is barely a year old. The company was formed in November 2025 through the merger of atai Life Sciences [a Berlin-founded clinical-stage company built by investor Christian Angermayer] and Beckley Psytech, its British counterpart. Angermayer, who remained the company’s largest individual shareholder and chaired the board through the deal process, described the sale as “the best path forward for patients and shareholders.”

Lilly is the third large pharmaceutical company to commit to the psychedelics space in under a year. AbbVie paid $1.2 billion for Gilgamesh Pharmaceuticals’ candidate bretisilocin in August 2025. Otsuka acquired Transcend Therapeutics for the same sum in June 2026. The commercial proof-of-concept behind all three deals is J&J’s Spravato – an esketamine nasal spray that generated $2 billion in sales in 2025 and demonstrated that psychedelic-adjacent treatments can clear the payer bar in real-world clinical settings.

By the time the AtaiBeckley agreement was announced, Lilly had already spent more than $10 billion [!] upfront across 11 acquisitions in 2026 – more than any other pharmaceutical company. AtaiBeckley represents its first direct entry into psychedelic medicine.

This deal effectively ends the debate about Big Pharma’s appetite for psychedelic medicine and opens a much harder one about infrastructure. The clinical science on neuroplastogens has been accumulating for two years. Lilly’s capital and distribution reach now attach a credible commercialization engine to that science. For practitioners, operators, and investors monitoring Cannabis-adjacent and psychedelic wellness sectors, the more urgent question is how quickly payers and regulators can build the reimbursement and clinical-access framework these drugs will need.